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Abstract
Background: Visceral leishmaniasis (VL), i.e., infection with Leishmania sp. associated with high fever, weight loss,
massive splenomegaly and markedly altered laboratory parameters, is generally fatal if untreated. The possibility of
transient spontaneous remission of fully symptomatic visceral leishmaniasis (VL) has been mentioned but, to our
knowledge) has never been documented.
Case presentation: We report the first documented history of a patient with overt, confirmed VL experiencing
a complete remission in the absence of any anti-leishmanial therapy. The diagnosis of VL at the time of the
self-resolving episode was strongly suspected based on clinical presentation and presence of antileishmanial
antibody, then unequivocally confirmed years later by the presence of an amastigote on a stored smear and
the positive quantitative PCR with Leishmania-specific primers from the material scraped from this same slide
Conclusion: This report demonstrates that complete spontaneous remission may occur in patients with overt, fully
symptomatic VL. VL should therefore be considered in cases of self-resolving or relapsing episodes of fever of unknown
origin. Confirmation should be based on both serological tests and specific PCR on a blood sample.
Keywords: Visceral leishmaniasis, Spontaneous remission, Hemophagocytic lymphohistiocytosis, Real time PCR, Giemsa
stained, Bone marrow smear
Background
Overt visceral leishmaniasis, i.e., infection with Leish-
mania sp. associated with high fever, weight loss, massive
splenomegaly and markedly altered laboratory parameters,
is generally considered fatal if untreated [1, 2]. The possi-
bility of transient spontaneous remission has been men-
tioned [3] but, to our knowledge, has never been precisely
documented because patients with documented VL are
treated. We provide the first description of a complete,
prolonged remission of fully symptomatic VL in a patient
who had not received any anti-leishmanial therapy.
Case presentation
In July 2008, a 27-year-old immunocompetent male pa-
tient was referred to our hospital for a 3-week history of
fever, asthenia and pancytopenia. The patient had spent
4 month in an area endemic for Leishmania infantum in
the South of France (Oriental Pyrennees). His medical
history included dental infections and an allergy to
methicillin. He reported two similar episodes of high
fever and asthenia in 2006 (Table 1). The first episode in
June 2006 had resolved spontaneously. During the sec-
ond episode, in November, the patient was hospitalized
with splenomegaly (17 cm), fever (40 °C) and weight loss
(10 kg), anemia, leucopenia and thrombocytopenia
(Table 1). Microscopic examination of a bone marrow
(BM) aspirate was negative for parasites. The bone
marrow smear showed normal cellularity and there was
no indication of immunosuppression. All microbiological
and immunological tests were negative (blood and urine
culture, testing for HIV, salmonella, brucellosis, Lyme
borreliosis, hepatitis A, cytomegalovirus infection, arbo-
viral infection, and malaria) except for positive titers of
anti-Leishmania antibody (IFA 1/400) and a positive
serology for EBV suggestive of prior infection. In this
context of fever of unknown origin, a presumptive 8-day
course of intravenous antibiotic therapy (ceftriaxone and
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ofloxacin) was administered. All signs and symptoms,
including fever, splenomegaly and asthenia, resolved in
4 weeks. No specific anti-leishmanial drug had been
administered, as the treating physician had not retained
this diagnosis. All laboratory parameters normalized
during the same period, confirming complete remission
of the episode (Table 1).
In 2008, relapse occurred with weight loss (4 kg), fever
(40 °C) and arthralgia (Table 1). Physical examination
showed an enlarged spleen, measuring 20 cm on the
subsequent CT scan. Antinuclear antibodies were posi-
tive (dilution of 1/1280) with a nonspecific pattern. The
bone marrow (BM) aspirate showed hemophagocytosis.
All microbiological tests, including Histoplasma capsula-
tum antibody were negative except anti-leishmanial anti-
body titers that were again positive (ELISA >1.7 for a
threshold at 1). Quantitative polymerase chain reaction
(PCR) on a L. infantum kinetoplast DNA target found
30 parasites per mL, i.e., above the threshold for active
VL (1 parasite/ml) [4]. Blood and BM cultures for L.
infantum were negative.
Fever lasted 4 weeks before the diagnosis of VL was
confirmed. The patient was then treated with liposomal
Amphotericin B (l-AmB) (3 mg/kg/day D1-5 and D10)
[5]. Complete fever resolution was obtained in 3 days
along with a dramatic improvement of the patient’s gen-
eral well-being. Ultrasonography showed regression of
splenomegaly from 20 to 14 cm at the end of the first
week, followed by normalization to 12 cm 6 months
later. At that time laboratory parameters had returned to
normal levels (Table 1) and quantitative PCR for L.
infantum was negative. When last seen, in September
2010, the patient was completely asymptomatic.
We reexamined a bone marrow smear performed in
2006 during the first hospitalization. Independent,
complete examination of this smear by 2 observers
(10 h of observation under the microscope) revealed
the presence of a single typical amastigote form of
Leishmania sp. (Fig. 1). Material on the smear was
then thoroughly scarped from the slide with a blade
and resuspended in 30 μl of sterile distilled water.
Real time PCR amplification was performed in a thermal
cycler TAQMAN® (Applied Biosystems) using Leishmania
kDNA specific primers as described by Mary et al. [4].
One negative blood slide and one negative tissue slide
were used as controls. Amplification of the material re-
trieved from the slide occurred at 28 CTs, corresponding
to the presence of 1.8 parasites (Fig. 1).
Discussion
This is the first documented report of a patient with
overt, confirmed VL experiencing a complete remission
in the absence of any anti-leishmanial therapy. The diag-
nosis of VL at the time of the self-resolving episode was
strongly suspected based on clinical presentation and
presence of antileishmanial antibody, then unequivocally
confirmed years later by the presence of an amastigote
on a stored smear. Quantitative PCR from the material
scraped from this same slide using Leishmania-specific
primers was positive. The excellent specificity of this
Table 1
2006 Nov. 13th 2007, Feb. 1st 2008, July 2nd 2008, July 11th 2008, July 21st 2009, Jan. 15th
Antileishmanial agent L-AmB Day1 L-AmB Day10
Antimicrobial agents Ciprofloxacin ceftriaxone
Clinical parameters
Temperature (°C) 40 37 40 38.2 36.1 36.5
Weight (kg) 59 73 68 72
Biological parameters
White blood cell count (/mL) 1.480 7.000 1.280 0.990 4.110 9.200
Neutrophils (/mL) 0.720 4.018 0.563 0.495 1.993 6.522
Lymphocytes (/mL) 0.650 2.065 0.640 0.455 1.780 1.536
Hemoglobin (g/dL) 9.6 14.8 9.9 9.1 11.6 16.2
Platelet count (/mL) 87.000 197.000 75.000 64.000 250.000 182.000
ASAT (IU/L) 126 21 51 93 20
ALAT (IU/L) 56 18 15 19 17
C-reactive protein (mg/L) 160 1.9 63 97 4
Ferritin (μg/L) 19.295 57 2.093
Fibrinogen (g/l) 2.5 3.5 3.5
Triglycerides (mmol/L) 2.32 2.21
LDH (IU/L) 1.400 250 1.010
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PCR has been confirmed by several teams [4, 6–9]. The
last episode, during which PCR was positive in a blood
sample was followed by a positive outcome under anti-
leishmanial therapy with liposomal amphotericin B. No
relapse occurred during the 2 years following administra-
tion of anti-leishmanial therapy, which is consistent with
the high efficacy of l-AmB in Mediterranean VL [10].
It has been known for decades that patients with mild
symptoms of VL may recover spontaneously and that a
minority eventually develop overt clinical VL [11]. In L.
infantum transmission foci, asymptomatic infections and
mild clinical forms of VL are indeed frequent in humans
[12, 13]. This is different from the spontaneous remission
of fully symptomatic severe VL, as described here. Uncon-
trolled studies that show improvement or apparent cure in
patients receiving experimental anti-leishmanial interven-
tions for overt VL should thus be interpreted cautiously
[14, 15]. We cannot definitely exclude the hypothesis
that the short course of intravenous antibiotic therapy
(ceftriaxone and ofloxacin during 8 days) during the
first episode may have contributed to the patient's im-
provement. A few reports in vitro or in animals suggest
indeed that quinolones may have some activity against
Leishmania [16–18] thus possibly contributing to the
control of parasite loads. Thereafter, the patient was appro-
priately treated and cured with liposomal Amphotericin B.
For confirmation of VL, PCR in the blood is more sensi-
tive than conventional search of the parasite even in bone
marrow aspirates. Time spent for reading Giemsa-stained
smears in the search for Leishmania amastigotes increases
the test sensitivity that raises to 95.4 % after 60 min and
89.7 % when 1.200 fields are examined [19]. When a
macrophage activation syndrome is present, repetition of
bone marrow aspirates also increases diagnostic sensitivity
[20]. Why patients would spontaneously recover from
overt VL is not clear. Interestingly, our patient met five out
Fig 1 Amplification profile in RT-PCR of the Giemsa slide of the bone marrow smear, the negative blood slide and the negative tissue slide, the
amplification of the Leishmania kinetoplast DNA is labeled in orange and the amplification of the DNA of the Internal Positive Control
(IPC) is labeled in Grey. The amplification of the kinetoplast DNA of Leishmania from the Giemsa slide of the bone marrow smear is indicated
by red vertical dotted line and occurred at 28 CTs which corresponds to the presence of 1.8 parasites on the slide. The amplification of the kinetoplast
DNA of Leishmania from the five positive points of the range are indicated by blue vertical dotted lines. Typical amastigote form of Leishmania sp
(2–3 mm in diameter) seen in smear bone marrow shown in insert squares at the left side of the figure. The nucleus and kinetoplast are
in red arrow. Staining May Grunwald Giemsa (MGG) x1000. *Parasite
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of the eight criteria of the hemophagocytic lymphohistiocy-
tosis (HLH-2004 revised diagnostic guidelines) [21]. There-
fore, if HLH had also occurred during the initial episode,
phagocytosis of Leishmania-infected cells by previously ac-
tivated macrophages, or a general activation of macro-
phages as observed in HLH, may have contributed to the
control of parasite loads. This hypothesis is consistent with
the absence of Leishmania amastigotes in bone marrow as-
pirates in 36.3 % of patients with VL and HLH [22].
Conclusion
In summary, this report demonstrates that complete spon-
taneous remission may occur in patients with overt, fully
symptomatic VL. VL should therefore be considered in
cases of self-resolving or relapsing episodes of fever of un-
known origin. Confirmation should be based on both
serological tests and specific PCR on a blood sample.
Consent
Patient was informed of the process by this attending phys-
ician using a procedure common to all French National
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montp1.fr/conseil.htm) and gave his oral consent for data
collection and publication. Mention of this consent was
written in the medical chart.
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